ArticleAmerican journal of translational research2025
Enhanced clinical outcome and safety of Danhong injection combined with aspirin and clopidogrel for acute ischemic stroke: a retrospective study.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effects of evolocumab combined with statin therapy on blood lipids, inflammatory factors, and endothelial function in patients with coronary heart disease.BMC cardiovascular disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy and safety of Danhong injection combined with dual antiplatelet therapy (DAPT) in patients with acute ischemic stroke (AIS).
methodsA retrospective analysis was conducted on 110 AIS patients (aged 40-80 years, National Institutes of Health Stroke Scale 3-15) admitted between October 2021 and October 2023. Patients were divided into two groups: the intervention group (n=55) received Danhong injection (40 mL/day for 14 days) plus DAPT (aspirin 100 mg + clopidogrel 75 mg), while the control group (n=55) received DAPT alone. Primary outcomes included neurological function, infarct volume, and inflammatory/hemorheological markers. Safety was also assessed.
resultsThe intervention group showed greater neurological improvement, with NIHSS scores decreasing from 8.2 to 3.2 compared to 8.5 to 5.1 in the control group (P<0.001). Functional independence rate was higher in the intervention group (81.8% vs. 54.5%, P=0.002). Infarct volume reduction was more pronounced in the intervention group (5.0 cm
conclusionDanhong injection combined with DAPT significantly enhanced neurological recovery, reduced infarct volume, and modulated systemic inflammation in AIS patients, with a favorable safety profile.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.